https://www.drugdevletter.com/archivedailyhttps://www.drugdevletter.com/aboutweeklyhttps://www.drugdevletter.com/podcastweeklyhttps://www.drugdevletter.com/p/can-i-confidently-say-to-patients2025-08-07monthlyhttps://www.drugdevletter.com/p/the-online-breaking-ice-app-out-in2025-08-03monthlyhttps://www.drugdevletter.com/p/does-a-3-year-structured-exercise2025-07-31monthlyhttps://www.drugdevletter.com/p/lunar-full-moon-or-eclipse-an-exploration2025-04-17monthlyhttps://www.drugdevletter.com/p/how-to-appraise-the-control-arm-in2025-04-11monthlyhttps://www.drugdevletter.com/p/surrogate-end-points-in-oncology2025-03-25monthlyhttps://www.drugdevletter.com/p/the-19th-st-gallen-breast-oncology2025-03-09monthlyhttps://www.drugdevletter.com/p/the-duck-test-for-huey-dewey-and2025-03-06monthlyhttps://www.drugdevletter.com/p/cdk46-inhibitors-and-novel-adjuvant2025-03-04monthlyhttps://www.drugdevletter.com/p/vaccine-safety-research-too-much2025-02-25monthlyhttps://www.drugdevletter.com/p/the-cabinet-study2025-02-21monthlyhttps://www.drugdevletter.com/p/excessive-drug-price-leads-to-hefty2025-02-19monthlyhttps://www.drugdevletter.com/p/did-pembrolizumab-improve-survival2025-02-09monthlyhttps://www.drugdevletter.com/p/home-grown-car-t-cells-a-blessing2025-02-05monthlyhttps://www.drugdevletter.com/p/the-landscape-of-checkpoint-inhibitors-16a2025-01-30monthlyhttps://www.drugdevletter.com/p/one-arena-where-you-can-bend-the2025-01-18monthlyhttps://www.drugdevletter.com/p/does-the-clinical-value-of-a-drug2025-01-05monthlyhttps://www.drugdevletter.com/p/analyzing-asco-tweets-social-media2024-12-31monthlyhttps://www.drugdevletter.com/p/boxing-day-reflections-and-new-year2024-12-29monthlyhttps://www.drugdevletter.com/p/the-landscape-of-checkpoint-inhibitors2024-12-27monthlyhttps://www.drugdevletter.com/p/randomized-versus-real-world-evidence2024-12-15monthlyhttps://www.drugdevletter.com/p/can-quality-of-life-research-learn2024-11-24monthlyhttps://www.drugdevletter.com/p/how-to-design-a-trial-to-test-the2024-11-22monthlyhttps://www.drugdevletter.com/p/splash-a-problematic-trial-design2024-11-18monthlyhttps://www.drugdevletter.com/p/after-23-years-imatinib-remains-the2024-11-04monthlyhttps://www.drugdevletter.com/p/special-post-esmo-2024-edition2024-11-03monthlyhttps://www.drugdevletter.com/p/artificial-intelligence-in-medicine2024-10-29monthlyhttps://www.drugdevletter.com/p/debate-over-pembrolizumab-dosing2024-10-16monthlyhttps://www.drugdevletter.com/p/challenges-with-reproducibility2024-09-26monthlyhttps://www.drugdevletter.com/p/lu-psma-and-the-need-to-educate-medical2024-09-25monthlyhttps://www.drugdevletter.com/p/immune-checkpoint-inhibitors-10-year2024-09-23monthlyhttps://www.drugdevletter.com/p/the-scattergun-approach-in-research2024-09-22monthlyhttps://www.drugdevletter.com/p/should-us-taxpayers-have-payed-for2024-09-17monthlyhttps://www.drugdevletter.com/p/an-educational-opportunity-esmo20242024-09-17monthlyhttps://www.drugdevletter.com/p/special-esmo-2024-edition2024-09-15monthlyhttps://www.drugdevletter.com/p/what-is-a-seeding-trial-tivozanib2024-09-13monthlyhttps://www.drugdevletter.com/p/driver-mutation-lung-cancer2024-09-09monthlyhttps://www.drugdevletter.com/p/tislelizumab-a-novel-anti-pd1-in2024-09-08monthlyhttps://www.drugdevletter.com/p/fda-agnostic-approvals-in-rare-cancers2024-08-31monthlyhttps://www.drugdevletter.com/p/why-should-a-top-fda-official-unilaterally2024-08-01monthlyhttps://www.drugdevletter.com/p/response-rate-tricks-in-oncology2024-07-19monthlyhttps://www.drugdevletter.com/p/project-orbis-harmonizing-up-or-down2024-07-12monthlyhttps://www.drugdevletter.com/p/eli-lillys-court-victory-dutch-agency2024-07-07monthlyhttps://www.drugdevletter.com/p/cdk46-inhibitors-as-adjuvant-therapy2024-07-03monthlyhttps://www.drugdevletter.com/p/are-patient-advocacy-groups-free2024-06-30monthlyhttps://www.drugdevletter.com/p/theoremm-a-novel-framework-for-cancer2024-06-27monthlyhttps://www.drugdevletter.com/p/should-the-laura-trial-change-our2024-06-26monthlyhttps://www.drugdevletter.com/p/postrecurrence-treatment-in-neoadjuvant2024-06-20monthlyhttps://www.drugdevletter.com/p/editors-pick-overdiagnosis-and-overtreatment2024-06-18monthlyhttps://www.drugdevletter.com/p/special-post-for-our-french-speaking2024-06-12monthlyhttps://www.drugdevletter.com/p/special-post-asco-2024-edition2024-06-09monthlyhttps://www.drugdevletter.com/p/my-2-hour-lecture-at-asco-on-critical2025-03-19monthlyhttps://www.drugdevletter.com/p/quality-of-life-in-the-adjuvant-setting2024-06-05monthlyhttps://www.drugdevletter.com/p/imatinib-is-still-better-first-than2024-06-10monthlyhttps://www.drugdevletter.com/p/is-the-crown-deserved-unsure-plus2024-05-31monthlyhttps://www.drugdevletter.com/p/asco-pre-game-show2024-05-30monthlyhttps://www.drugdevletter.com/p/are-you-coming-to-asco-2024-to-learn2024-05-29monthlyhttps://www.drugdevletter.com/p/fda-censoring-rules-doubling-the2024-05-27monthlyhttps://www.drugdevletter.com/p/low-dose-dexamethasone-in-patients2024-05-24monthlyhttps://www.drugdevletter.com/p/cdk46-inhibitors-in-novel-adjuvant2024-05-23monthlyhttps://www.drugdevletter.com/p/de-escalation-in-1-pd-l1-metastatic2024-05-22monthlyhttps://www.drugdevletter.com/p/do-patients-survive-longer-because2024-05-21monthlyhttps://www.drugdevletter.com/p/destiny-breast06-why-i-hope-there2024-05-20monthlyhttps://www.drugdevletter.com/p/how-to-do-a-great-cancer-journal2024-05-18monthlyhttps://www.drugdevletter.com/p/fridays-gem-overall-survival-in-first2024-05-17monthlyhttps://www.drugdevletter.com/p/what-to-expect-from-the-laura-trial2024-05-15monthlyhttps://www.drugdevletter.com/p/how-the-money-flows-at-haematology2024-05-13monthlyhttps://www.drugdevletter.com/p/fridays-gem-editors-pick2024-05-10monthlyhttps://www.drugdevletter.com/p/car-t-cells-in-multiple-myeloma-82024-05-09monthlyhttps://www.drugdevletter.com/p/neoadjuvant-immunotherapy-in-patients2024-05-08monthlyhttps://www.drugdevletter.com/p/cisplatin-shortage-has-costs-beyond2024-05-06monthlyhttps://www.drugdevletter.com/p/the-drug-development-letter-gets2024-05-04monthlyhttps://www.drugdevletter.com/p/sotorasib-kras-g12c-a-regulatory2025-04-02monthlyhttps://www.drugdevletter.com/p/the-us-fdas-cancer-drug-approval2024-04-25monthlyhttps://www.drugdevletter.com/p/how-many-people-benefit-from-car2024-02-14monthlyhttps://www.drugdevletter.com/p/car-t-cells-linked-to-secondary-amlmds2023-12-24monthlyhttps://www.drugdevletter.com/p/ash-update-with-aaron-goodman2023-12-20monthlyhttps://www.drugdevletter.com/p/observational-studies-and-randomized2023-11-05monthlyhttps://www.drugdevletter.com/p/hla-based-therapeutics-an-entire2023-10-31monthlyhttps://www.drugdevletter.com/p/how-to-read-and-interpret-kaplan2025-04-17monthlyhttps://www.drugdevletter.com/p/giving-adjuvant-xeloda-to-biliary2023-09-13monthlyhttps://www.drugdevletter.com/p/anticoagulating-people-forever-after2023-09-03monthlyhttps://www.drugdevletter.com/p/how-much-money-do-we-waste-when-cancer2023-07-24monthlyhttps://www.drugdevletter.com/p/adaura-trial-an-unethical-trial2023-06-08monthlyhttps://www.drugdevletter.com/p/treatment-after-progression-in-oncology2023-05-25monthlyhttps://www.drugdevletter.com/p/how-to-read-and-interpret-a-cancer2023-05-04monthlyhttps://www.drugdevletter.com/p/abbvie-voluntarily-recalls-ibrutinib2023-04-07monthlyhttps://www.drugdevletter.com/p/can-altering-the-microbiome-improve2023-04-01monthlyhttps://www.drugdevletter.com/p/tumor-agnostic-drugs-are-not-tumor2023-03-28monthlyhttps://www.drugdevletter.com/p/real-world-evidence-danish-keynote2023-03-26monthlyhttps://www.drugdevletter.com/p/zuma-7-crossover-rate-confirmed2023-03-23monthlyhttps://www.drugdevletter.com/p/zuma-7-has-os-benefit-not-so-fast2023-03-22monthlyhttps://www.drugdevletter.com/p/the-starting-dose-is-fair-but-that2023-03-21monthlyhttps://www.drugdevletter.com/p/relapsed-cancer-patients-die-so-asymptomatic2023-03-17monthlyhttps://www.drugdevletter.com/p/new-jama-paper-mrd-in-aml-prior-to2023-03-09monthlyhttps://www.drugdevletter.com/p/ida-cel-or-standard-regimens2023-03-07monthlyhttps://www.drugdevletter.com/p/which-drugs-is-medicare-expected2023-03-04monthlyhttps://www.drugdevletter.com/p/more-on-randomized-trials-equivalence2023-03-03monthlyhttps://www.drugdevletter.com/p/dostarlimab-in-mismatch-repair-deficient2023-03-01monthlyhttps://www.drugdevletter.com/p/codebreak-200-and-sotorasib2023-02-28monthlyhttps://www.drugdevletter.com/p/randomized-trials-the-basics2023-02-28monthlyhttps://www.drugdevletter.com/p/how-to-search-for-negotiate-and-choose2023-02-27monthlyhttps://www.drugdevletter.com/p/psma-pet-scans-just-because-it-is2023-02-21monthlyhttps://www.drugdevletter.com/p/rucaparib-vs-investigator-choice2023-02-20monthlyhttps://www.drugdevletter.com/p/coming-soon2023-02-13monthly